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Abstract
Background: Suspected recurrence of thyroid carcinoma is a diagnostic challenge when findings of both a radio
iodine whole body scan and ultrasound are negative. PET/CT and MRI have shown to be feasible for detection of
recurrent disease. However, the added value of a consensus reading by the radiologist and the nuclear medicine
physician, which has been deemed to be helpful in clinical routines, has not been investigated. This study aimed to
investigate the impact of combined FDG-PET/ldCT and MRI on detection of locally recurrent TC and nodal
metastases in high-risk patients with special focus on the value of the multidisciplinary consensus reading.
Materials and methods: Forty-six patients with suspected locally recurrent thyroid cancer or nodal metastases
after thyroidectomy and radio-iodine therapy were retrospectively selected for analysis. Inclusion criteria comprised
elevated thyroglobulin blood levels, a negative ultrasound, negative iodine whole body scan, as well as combined
FDG-PET/ldCT and MRI examinations.
Neck compartments in FDG-PET/ldCT and MRI examinations were independently analyzed by two blinded
observers for local recurrence and nodal metastases of thyroid cancer. Consecutively, the scans were read in
consensus. To explore a possible synergistic effect, FDG-PET/ldCT and MRI results were combined. Histopathology
or long-term follow-up served as a gold standard.
For method comparison, sensitivity, specificity, positive and negative predictive values, and diagnostic accuracy
were calculated.
Results: FDG-PET/ldCT was substantially more sensitive and more specific than MRI in detection of both local
recurrence and nodal metastases. Inter-observer agreement was substantial both for local recurrence (κ = 0.71) and
nodal metastasis (κ = 0.63) detection in FDG-PET/ldCT. For MRI, inter-observer agreement was substantial for local
recurrence (κ = 0.69) and moderate for nodal metastasis (κ = 0.55) detection. In contrast, FDG-PET/ldCT and MRI
showed only slight agreement (κ = 0.21). However, both imaging modalities identified different true positive results.
Thus, the combination created a synergistic effect. The multidisciplinary consensus reading further increased
sensitivity, specificity, and diagnostic accuracy.
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Conclusions: FDG-PET/ldCT and MRI are complementary imaging modalities and should be combined to improve
detection of local recurrence and nodal metastases of thyroid cancer in high-risk patients. The multidisciplinary
consensus reading is a key element in the diagnostic approach.
Keywords: PET/CT, MRI, Recurrent thyroid cancer, Recurrent thyroid carcinoma, Thyroid cancer, Nodal metastases,
Lymph node metastases, Consensus reading, Iodine-negative, Negative ultrasound
Background
Thyroid carcinoma (TC) is a rare malignancy. Nonethe-
less, the incidence has grown markedly since the early
1990s. In 2010 the standardized incidence in the US was
estimated at 6.0/100,000 in males and 17.3/100,000 in
females [1, 2]. In Europe, the standardized incidence
ranges from 2.03/100,000 to 5.0/100,000 in males and
from 5.65/100,000 to 15.50/100,000 in females [3]. TC
has a relatively high rate of local recurrence and lymph
node or soft tissue metastases; estimates range between
20 and 30 % [4, 5]. Distant metastases develop in up to
15 % of cases, primarily as pulmonary metastases,
followed by bone metastases [6]. Prognosis primarily de-
pends on the site of recurrence and the subsequent
treatment, and early diagnosis of recurrence is of utmost
importance to determine whether or not a salvage sur-
gery is possible. Therefore, a close postoperative follow-
up regime is mandatory [7].
Currently, the most frequently used modalities for post-
thyroidectomy follow-up examinations are neck ultrasound
(US), measuring thyroglobulin (Tg) blood levels, and radio-
iodine 131I-whole-body scan (I-WBS) [7–9]. However, 20–
40 % of the patients with recurrent TC or nodal metastases
lose their ability to accumulate radioactive iodine due to
tumor cell dedifferentiation. Thus, they are not visible on I-
WBS. In this case, alternative imaging modalities are
needed, such as 18F-fluorodeoxyglucose Positron emission
tomography (FDG-PET), 18F-fluorodeoxyglucose-PET/
computed tomography (FDG-PET/CT), Magnetic reson-
ance imagining (MRI), or even 18F-fluorodeoxyglucose-
PET/MRI (FDG-PET/MRI) [5, 10–12].
FDG-PET was shown to be a useful tool in the
localization of disease in patients with elevated Tg levels
and negative US and I-WBS [13, 14]. It was quickly out-
performed by FDG-PET/CT, which combined the advan-
tages of metabolic and morphologic imaging and thus
allowed for improved anatomic localization and correl-
ation of focal metabolic activity. FDG-PET/CT is now
commonly accepted as the method of choice for post-
thyroidectomy patients with increased Tg blood levels and
negative I-WBS [11, 12, 15–18]. For distant metastases,
particularly of the lung and bones, FDG-PET/CT reaches
both sensitivity and specificity up to 1.00 [14, 15, 19].
Nonetheless, the sensitivity and specificity of FDG-PET/
CT for detecting locally recurrent or metastatic TC is still
relatively low and ranges between 0.46 to 1.00 and 0.66 to
1.00, respectively [5, 12, 17]. Furthermore, recurrent, re-
sidual, or metastatic tissue does not always accumulate
18FDG, and thus remains undetectable by FDG-PET/CT.
Hence, supplementary imaging modalities are occasionally
required.
MRI is the primary imaging modality for soft tissue
tumors due to its excellent soft tissue contrast, add-
itional functional imaging capabilities, and reduced
dental metal artifacts in the head and neck, as com-
pared to FDG-PET/CT [20–23]. MRI of the neck is
mainly used for planning the surgical approach and
postoperative follow-up in head and neck cancer and
TC patients. Its specific application for TC has fre-
quently been described in the literature [22, 24, 25].
The sensitivity and specificity of MRI in detecting lo-
cally recurrent or metastatic TC ranges from 0.76 to
0.95 and 0.51 to 0.98, respectively [4, 22, 24, 26]. Be-
cause of its superior soft tissue contrast and its ability
to detect non-iodine-avid and FDG-negative tumor
tissue, MRI appears to be a powerful complementary
imaging modality to FDG-PET/CT [4, 22, 23, 26, 27].
Additionally, gadolinium-based MRI-contrast media
avoids iodine contamination before curative radioio-
dine therapy [4, 23]. PET/MRI is a new hybrid im-
aging modality that has been applied to TC. Initial
results suggested PET/MRI was superior to PET/CT
in detecting iodine-positive lesions [28], but for evalu-
ating the primary disease in the neck area it per-
formed as well as contrast-enhanced PET/CT [29].
However, PET/CT was superior to PET/MRI in asses-
sing pulmonary status [30].
A systematic assessment of the added value of 18F-
fluorodeoxyglucose-PET/low dose computed tomog-
raphy (FDG-PET/ldCT) and MRI for detecting locally
recurrent TC or cervical nodal metastases has not yet
been reported in the literature. Also, the added value
of a consensus reading between a nuclear medicine
physician and a radiologist, which we have found to be
very helpful in clinical routine, has not been investi-
gated. Therefore, this study aimed to evaluate the im-
pact of combined FDG-PET/ldCT and MRI on the
detection of local recurrence and cervical nodal me-
tastases of TC. Furthermore, it attempted to quantify
the value of a multidisciplinary consensus reading.
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Methods
Study design, ethics, and study group
This study followed all procedures laid out in the ethical
standards of the responsible committee on human ex-
perimentation and with the revised version of the
Helsinki Declaration of 1975. All patients were referred
to departments of radiology and nuclear medicine as in-
dicated by clinical need and received sequential MRI
and FDG-PET/ldCT scans for postoperative follow-up.
No additional radiation dose was applied. Patient re-
cords and information were de-identified prior to ana-
lysis by the department’s information technology service.
Institutional review board approval was waived, given
that this study utilized the retrospective analysis of
blinded clinical data.
This was a retrospective diagnostic study. Forty-six
consecutive TC patients who underwent thyroidectomy
and radio iodine therapy with ongoing suspicion of re-
current local or metastatic disease were reviewed by our
multidisciplinary tumor board between June 2008 and
November 2012. The inclusion criteria included elevated
Tg blood level, negative ultrasound and I-WBS (diagnos-
tic rhTSH stimulated I-WBS with administered activity
of 370 or 3700 MBq) as well as combined FDG-PET/
ldCT and MRI examinations that occurred within 72 h
of one another. Tg blood levels above 2 μg/l were de-
fined as clearly pathological. However, in some patients
with high risk profile (e.g., lymph node metastases in
clinical history) Tg values below 2 μg/l were considered
as suspicious. Patients with a medullary subtype of TC
were excluded.
Table 1 shows demographic and disease-related infor-
mation of the study patients.
Procedures and techniques
PACS-Viewer
Images were analyzed using the TeraRecon Aquarius
thin client® viewer (TeraRecon, Inc., CA, USA).
FDG-PET/ldCT
PET/CT of the whole body was acquired on a Gemini®
TF 16 PET/CT (Philips, Best, the Netherlands) 60 min
after the application of 18F-fluorodeoxyglucose (2–
2.5 MBq/kg). A fasting period of more than six hours
before application was mandatory for all patients. For at-
tenuation correction, low dose CT without application
of contrast media was used.
MRI
Examinations of the cervical region were acquired
with Magnetom Sonata® 1.5 T, Magnetom Avanto®
1.5 T, Magnetom Espree® 1.5 T, and Magnetom Skyra®
3 T (all Siemens Healthcare, Erlangen, Germany).
Due to variations between the scan protocols, only
axial short tau inversion recovery (STIR)-weighted se-
quence, axial T1-weighted turbo spin echo (TSE) se-
quence, and Gadolinium contrast media enhanced
(Dotarem®, Guerbet, France) axial T1-weighted TSE se-
quences with fat suppression were selected for study
analysis.
Image analysis and definition of results
The FDG-PET/ldCT studies were independently ana-
lyzed by two blinded physicians who both had board
Table 1 Descriptive demographic and disease-related data of
all study patients
Total number of consecutive
study patients
46
Age (median, interquartile range) 70 (58-80)
Sex Male 27 (59 %)
Female 19 (41 %)










Histopathology Follicular 16 (35 %)




Anaplastic 1 (2 %)
Stage of disease I 3 (6 %)
II 2 (4 %)
III 5 (11 %)
Iva 8 (18 %)
IVb 2 (4 %)
IVc 24 (53 %)
x 2 (4 %)
Primary tumor Ia 2 (4 %)
Ib 4 (9 %)
2 8 (18 %)
3 16 (35 %)
4 12 (25 %)
x 4 (9 %)
Regional lymph nodes 0 17 (37 %)
1a 9 (20 %)
1b 15 (33 %)
x 5 (10 %)
Distant metastasis 0 16 (35 %)
1 23 (50 %)
x 7 (15 %)
Staging of thyroid carcinoma according to the 7th edition of AJCC Cancer
Staging Manual 2010
TSH thyroid stimulating hormone, Tg thyroglobulin
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certification in nuclear medicine and with 9 (MM) and
25(MS) years of professional experience. The MRI stud-
ies were independently analyzed by two blinded physi-
cians who specialized in diagnostic radiology and who
had 27 (SSF) and 5 (JMH) years of experience with
cross-sectional imaging of the head and neck.
The area of the thyroid bed and cervical lymph node
basins in the FDG-PET/ldCT and MRI examinations
were analyzed for locally recurrent TC and nodal metas-
tases separately as well as non-split. In order to be able
to compare both imaging modalities, all pathology seen
in the FDG-PET/ldCT, which was located outside the
field of view covered by the MRI, was excluded for ana-
lysis. The test results were classified as either positive or
negative based on a qualitative visual analysis. If either
one or both of the two readers identified a pathologic
finding, the result was considered to be positive. Uncer-
tain findings were classified as negative. To explore the
possibilities for a synergistic effect, the results of the
FDG-PET/ldCT and MRI examinations were combined
as follows: If either both FDG-PET/ldCT and MRI or
one of each was positive, then the combined result was
determined to be positive. If both the FDG-PET/ldCT
and MRI findings were negative, then the combined re-
sult was classified as negative. The separate analyses
were followed by a consensus reading between the FDG-
PET/ldCT and MRI observers. Inter-observer agreement
was determined by means of Cohen’s kappa coefficient
(κ) and classified according to Landis and Koch [31].
Validity
The gold standard was defined as histopathological find-
ings (subgroup a, n = 20) or, if the patient did not receive
an operation for any reason, a negative long-term clinical
follow-up period of at least 3 years (subgroup b, n = 26).
In subgroup a 17 patients were operated as a result of the
findings of the FDG-PET/ldCT and MRI examinations,
whereas 3 patients underwent surgery in the subsequent
clinical course. Due to the high number of patients who
did not undergo surgery, we performed a separate sub-
group analysis on this group. The gold standard for locally
recurrent TC or nodal metastases was determined either
as “positive” or “negative”, respectively.
Method comparisons for detection of locally recurrent TC
and cervical nodal metastases
The findings of the FDG-PET/ldCT and MRI examina-
tions were independently compared to the gold standard
in a cross table analysis. Subsequently, the combined
FDG-PET/ldCT and MRI results were compared to the
gold standard. Finally, the results of the consensus read-
ing were compared to the gold standard and to the
combined FDG-PET/ldCT and MRI results. For each
comparison, the sensitivity, specificity, positive predictive
value (PPV), negative predictive value (NPV), and diag-
nostic accuracy were calculated.
Clinical relevance
To evaluate the clinical relevance of the detected im-
aging findings, we separately analyzed the therapeutic
consequences of the PET/CT and MRI examinations in
clinical routine. According to Wiebel et al. [32] the
FDG-PET/ldCT and MRI scans were considered to im-
pact the patient management if the “examinations iden-
tified disease that was not previously known and
resulted in an intervention”, if the scans “resulted in the
decision to not pursue a specific intervention”, or if the
scan “changed the extent of a planned surgery because
of additional disease identified” [32].
Statistical tests
Data analyses were performed using IBM SPSS Statistics®
Version 22 (IBM, NY, USA). Cohen’s kappa coefficient
was used to determine inter-observer agreement. For
method comparison, the sensitivity, specificity, PPV, and
NPV were calculated, and McNemar’s test for paired
samples was applied, where the level of significance was
set at α = 0.05.
Results
In the detection of both locally recurrent TC and nodal
metastases with FDG-PET/ldCT, there was a substantial
agreement between reader 1 and reader 2 (κ = 0.71 and
κ = 0.63, respectively). In the non-split analysis of detec-
tion of locally recurrent TC or nodal metastases we
found an almost perfect agreement between reader 1
and reader 2 (κ = 0.83).
In the detection of locally recurrent TC with MRI, there
was a substantial agreement between reader 1 and reader
2 (κ = 0.69), whereas in the detection of nodal metastases
with MRI there was only a moderate agreement (κ = 0.55).
In the non-split analysis of detection of locally recurrent
TC or nodal metastases we found a substantial agreement
between reader 1 and reader 2 (κ = 0.67).
In the detection of both locally recurrent TC and
nodal metastases, there was only slight to fair agreement
between the findings from the FDG-PET/ldCT and MRI
(κ = 0.21).
The sensitivity, specificity, PPV, NPV, and diagnostic
accuracy for detecting locally recurrent TC or lymph
node metastases are shown in Tables 2 and 3. The separ-
ate analyses for locally recurrent TC and nodal metasta-
ses are demonstrated in Additional files 1, 2, 3 and 4:
Tables S1–S4.
The FDG-PET/ldCT and MRI results had impact on
patient management in 23 of 46 patients (50 %): 14 pa-
tients (30 %) were operated on, 3 patients (7 %) under-
went surgery and radiotherapy, 3 patients (7 %) were
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irradiated, 2 patients (4 %) underwent radio iodine ther-
apy, and 1 patient (2 %) was treated with tyrosine kinase
inhibitor therapy. In 10 patients (22 %) with active dis-
ease, an active surveillance strategy was chosen for vari-
ous reasons, e.g., inoperable situation or poor general
condition.
Figure 1 shows the added value of FDG-PET/ldCT and
MRI for clearer identification of a locally recurrent TC.
Discussion
The purpose of this study was to investigate the impact of
combined FDG-PET/ldCT and MRI on detecting locally
recurrent TC and nodal metastases in high risk patients,
with a special focus on the value of a multidisciplinary
consensus reading.
The rise in use of diagnostic imaging, especially of
FDG-PET(/CT) in TC follow-up, leads to increased radi-
ation exposure and associated health costs [32–34]. Un-
necessary diagnosis and intervention of low-risk and
clinically non-significant disease remain a legitimate
concern [34]. However, it is important to note that the
imaging results analyzed in this study influenced patient
management in over 50 % of patients, of whom 17
(37 %) were operated. The high percentage of high-risk
patients with stage 4 disease may explain the higher per-
centage of changes in patient management than has
been recently reported in the literature with approxi-
mately 30 % [32]. However, the smaller number of pa-
tients in our study may have caused selection bias.
Our data showed moderate inter-observer agreement
in the detection of cervical nodal metastases with MRI.
In our opinion, this moderate agreement is due to the
fact that a reliable differentiation between malign and
benign lymph nodes that is solely based on morphologic
criteria is often not possible – a problem that is well-
known in the literature [4, 35].
With regards to the data validity as compared to the
heterogeneous gold standard there was a basic issue: If a
recurrent disease was suspected, then the patient usually
underwent surgery. Thus, over 80 % of the positive im-
aging results were confirmed by histopathology. In case
of clearly negative FDG-PET/ldCT and MRI results, or if
the patient was not suitable for surgery, no histologic
sample could be gathered. As a consequence, the posi-
tive predictive value was higher and the negative predict-
ive value was lower in the surgery subgroup.
Table 2 Detection of local recurrence or nodal metastases of thyroid cancer
Gold standard FDG-PET/ldCT MRI Combined FDG-PET/ldCT and MRI Consensus reading
- + - + - + - + Sum
HP - 2 1 1 2 1 2 2 1 3
+ 2 15 7 10 1 16 1 16 17
sum 4 16 8 12 2 18 3 17 20
FU - 19 2 15 6 14 7 19 2 21
+ 0 5 3 2 0 5 0 5 5
sum 19 7 18 8 14 12 19 7 26
Both - 21 3 16 8 15 9 21 3 24
+ 2 20 10 12 1 21 1 21 22
sum 23 23 26 20 16 30 22 24 46
Comparison of FDG-PET/ldCT, MRI, combined FDG-PET/ldCT and MRI, and consensus reading in detection of local recurrence or nodal metastases of
thyroid cancer
Subgroup analysis of different gold standard
HP histopathology, FU follow-up
Table 3 Diagnostic performance of FDG-PET/ldCT, MRI, combined FDG-PET/ldCT and MRI, and the consensus reading
FDG-PET/ldCT MRI combined FDG-PET/ldCT and MRI consensus reading
HP FU Both HP FU Both HP FU Both HP FU Both
Sensitivity 88 % 100 % 91 % 59 % 40 % 54 % 94 % 100 % 95 % 94 % 100 % 95 %
Specificity 67 % 90 % 87 % 33 % 71 % 67 % 33 % 67 % 62 % 67 % 90 % 87 %
PPV 94 % 71 % 87 % 83 % 25 % 60 % 89 % 42 % 70 % 94 % 71 % 87 %
NPV 50 % 100 % 91 % 12 % 83 % 61 % 50 % 100 % 94 % 67 % 100 % 95 %
Accuracy 85 % 92 % 89 % 55 % 65 % 61 % 85 % 73 % 78 % 90 % 92 % 91 %
Diagnostic performance of FDG-PET/ldCT, MRI, combined FDG-PET/ldCT and MRI, and the consensus reading in detection of local recurrence or nodal metastases
of thyroid cancer
Subgroup analysis of different gold standard
HP histopathology, FU follow-up, PPV positive predictive value, NPV negative predictive value
Hempel et al. Cancer Imaging  (2016) 16:37 Page 5 of 9
Comparing the individual imaging modalities, FDG-
PET/ldCT clearly outperformed MRI in detecting locally
recurrent TC by having a higher sensitivity, specificity,
PPV, NPV, and diagnostic accuracy. In the identification
of cervical nodal metastases, FDG-PET/ldCT had a
higher sensitivity and NPV than MRI, and an equal diag-
nostic accuracy. In non-split analysis FDG-PET/ldCT
also clearly outperformed MRI by having a higher sensi-
tivity, specificity, PPV, NPV, and diagnostic accuracy.
Our overall FDG-PET/ldCT and MRI results were within
the sensitivity and specificity range reported in the lit-
erature, where the metabolic PET component was de-
scribed as “the leading tool for the detection of tumor
recurrence, regardless of the anatomical imaging compo-
nent with which it is combined” [26]. Nonetheless, the
primary benefit of MRI lays in the precise morphologic
assessment and correlation of metabolic foci, and its use
in planning a surgical approach [7]. Additionally, MRI
correctly identified locally recurrent TC in one patient
with PET-negative disease.
The poor agreement between the FDG-PET/ldCT and
MRI results (κ = 0.21) most likely originated from their
basic methodic differences. In truth, both imaging mo-
dalities identified different true positive results and thus
demonstrate a synergistic effect for combining these re-
sults. The combination of FDG-PET/ldCT and MRI test
results primarily increased sensitivity and NPV. None-
theless, specificity, PPV, and diagnostic accuracy de-
creased markedly due to concomitant higher rates of
false positives. Thus, their combination is not appropri-
ate for clinical routine, for it would increase the rate of
subsequent interventions of potentially clinical non-
relevant disease. We found that the multidisciplinary
consensus reading was a key element in this dilemma. In
mammography screenings, for instance, the value of sec-
ond imaging and consensus reading has been extensively
Fig. 1 The added value of FDG-PET/ldCT for identifying a locally recurrent thyroid cancer with unspecific pretracheal finding via MRI. a STIR-
weighted MR image, b contrast-enhanced T1-weighted MR image, c FDG-PET, and d fused FDG-PET and CT
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discussed in the literature, which finally led to its
mandatory introduction in clinical practice [36, 37]. With
regards to TC, the influence of consensus reading on the
detection of locally recurrent tumor or nodal metastases
has not yet been sufficiently investigated in the literature.
Consensus interpretation in assessing FDG-PET/CT ex-
aminations have been reported to impact specificity by
considerably reducing the number of false positive find-
ings [11]. Correspondingly, for detecting local recurrence
or nodal metastases of TC, the consensus reading outper-
formed the combined FDG-PET/ldCT and MRI results by
increasing specificity, PPV, and diagnostic accuracy, while
maintaining sensitivity and NPV. Specifically, 5 false posi-
tive MRI results with suspicious morphological findings as
well as one false positive FDG-PET/ldCT result with
FDG-negative disease could have been corrected by means
of the consensus reading. However, it is of note that the
consensus reading could improve the sensitivity, NPV, and
diagnostic accuracy values of FDG-PET/ldCT only moder-
ately, which in turn stresses the importance of metabolic
PET imaging for detection of recurrent disease [26].
PET/MRI is a new emerging imaging modality with
highly limited availability in clinical practice. In TC the
first results suggest that FDG-PET/MRI is equal to con-
trast enhanced FDG-PET/CT in assessing cervical status.
Nonetheless, FDG-PET/ldCT was shown to be superior
to FDG-PET/MRI in assessing pulmonary status [30].
Therefore, Vrachimis et al. [30] suggested combined
PET/MRI and low dose CT of the lung as a powerful
diagnostic tool in patients with suspected recurrent TC.
Our study results may support this approach, insofar as
it combines the advantages of functional and morpho-
logical imaging with potentially highest possible level on
diagnostic performance as well as least possible radiation
dose. However, future studies should look deeper into
the clinical benefit of PET/MRI in the follow-up care of
post-thyroidectomy TC patients.
Limitations
Our study patients were examined with different MRI
scanners that had different field strengths, gradients, and
examination protocols. Despite this limitation, there was
a relatively high inter-observer agreement in the MRI
group. Secondly, many MRI examinations were per-
formed without additional diffusion-weighted imaging or
functional imaging, which may have decreased the sensi-
tivity and specificity of MRI. Thirdly, PET/CT was per-
formed in a "whole-body" approach, while MRI was only
performed in the neck region. This study focused on the
neck area in order to be able to compare these two im-
aging modalities. Of course, a whole-body approach with
PET/MRI allowing for a direct modality comparison
with PET/CT would have been desirable, but was not
feasible in our department. In addition, most of the
selected patients were negative for active disease. Given
the lower rate of positive findings, the sensitivity and spe-
cificity values were possibly subject to selection bias and
the excellent sensitivity, specificity, and overall accuracy
approaching 100 % may not hold up in larger samples.
However, the number of patients with suspected recurrent
or metastatic TC, negative US, and negative I-WBS is nat-
urally limited. Nonetheless, the size of our sample (n = 46)
is close to the calculated minimum sample size required
for paired comparison (n = 54), indicating increased prob-
ability for Type I Error (α) of 0.05, a Power (1-β) of 0.9,
and an expected sensitivity or specificity in group 1 of
0.95 and in group 2 of 0.8. Finally, the retrospective study
design is unable to truly assess the impact of MRI and
FDG-PET/ldCT on patient management, as clinical deci-
sions were based upon the original reports of these scans
and the review in multidisciplinary tumor board, not the
retrospective consensus review.
Conclusions
Our study results clearly demonstrate a synergistic effect
for combining FDG-PET/ldCT and MRI in detecting lo-
cally recurrent TC and cervical nodal metastases in
high-risk patients with negative ultrasound and I-WBS.
Imaging results notably influenced patient management.
Therefore, both complementary imaging modalities
should be used together in this specific clinical setting.
Finally, a multidisciplinary consensus reading between a
nuclear medicine physician and a radiologist is a crucial
element in this diagnostic approach.
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